Related Experiment Videos
Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology
R Joeres1, D Brachtel, H Gallenkamp
1Department of Internal Medicine, University of Würzburg.
Insights
Caffeine elimination varies in liver disease patients. Alcohol-induced liver cirrhosis significantly reduces caffeine clearance, while alcoholic fatty liver and primary biliary cirrhosis enhance it.
Area of Science:
- Pharmacokinetics
- Hepatology
- Drug Metabolism
Background:
- Caffeine is a widely consumed substance metabolized by the liver.
- Liver disease can significantly alter drug metabolism and elimination.
- Understanding caffeine clearance in various liver conditions is crucial for patient management.
Purpose of the Study:
- To investigate caffeine elimination rates in patients with diverse liver diseases.
- To compare caffeine clearance in cirrhotic and non-cirrhotic liver conditions.
- To identify correlations between liver disease etiology and caffeine metabolism.
Main Methods:
- Oral administration of 366 mg caffeine to 419 patients with various liver diseases and controls.
- Measurement of caffeine clearance (ml/min) in different etiological groups.
- Statistical comparison of caffeine clearance rates against a control group of healthy volunteers.
Main Results:
- Caffeine clearance was not significantly reduced in hepatitis B or NANB virus infections.
- Alcoholic cirrhosis showed significantly reduced caffeine clearance (36 +/- 44 ml/min).
- Alcoholic fatty liver (127 +/- 71 ml/min) and primary biliary cirrhosis (117 +/- 59 ml/min) demonstrated enhanced caffeine clearance.
Conclusions:
- Caffeine elimination is significantly impaired in alcoholic cirrhosis.
- Certain liver conditions, like alcoholic fatty liver and primary biliary cirrhosis, enhance caffeine clearance.
- Serum bilirubin levels correlate inversely with caffeine clearance in cirrhotic liver disease, but the underlying condition is also a key determinant.
Abstract:
Caffeine elimination was studied in 419 patients with cirrhotic and noncirrhotic liver disease of different etiology (hepatitis B virus infection n = 79; hepatitis NANB virus infection n = 74; ethanol-induced liver damage n = 143; primary biliary cirrhosis I-IV n = 63; cryptogenic liver cirrhosis n = 60) following oral administration of 366 mg caffeine. Caffeine clearance in the control group was 69 +/- 33 ml/min (age-matched healthy volunteers and patients without liver disease). Caffeine clearance in acute hepatitis B (70 +/- 60 ml/min) chronic persistent hepatitis B (81 +/- 56 ml/min), chronic aggressive hepatitis B (107 +/- 66 ml/min), posthepatitic liver cirrhosis B (84 +/- 62 ml/min), acute hepatitis NANB (94 +/- 69 ml/min), chronic persistent hepatitis NANB (122 +/- 60 ml/min), chronic aggressive hepatitis NANB (87 +/- 52 ml/min) and posthepatitic cirrhosis NANB (59 +/- 26 ml/min) is not reduced in comparison with controls. In patients with alcoholic fatty liver (127 +/- 71 ml/min, p < 0.05) caffeine clearance is enhanced, in alcoholic hepatitis (57 +/- 72 ml/min) comparable to controls and in alcoholic cirrhosis reduced (36 +/- 44 ml/min, p < 0.05). In primary biliary cirrhosis I-IV caffeine clearance is higher than in controls (117 +/- 59 ml/min, p < 0.05). In cirrhotic liver disease of different origin caffeine clearance is inversely related to the serum bilirubin level. However, the absolute value is determined in addition by the underlying disease.(ABSTRACT TRUNCATED AT 250 WORDS)